Protara Therapeutics, Inc. (TARA) stock
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.32−0.06 (-2.52%)
Close on Nov 17, 2026Market cap $137.10MP/E –Yield –
Protara Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Protara Therapeutics's total assets was $176.09M at Jun 30, 2026. For fiscal 2025 it was $209.47M, up 15.4% from the year before. Over ten years it grew 12.0% a year on average. The highest annual figure on record is $209.47M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.47M | +15.4% |
| FY2024 | Dec 31, 2024 | $181.45M | +129.8% |
| FY2023 | Dec 31, 2023 | $78.95M | -30.3% |
| FY2022 | Dec 31, 2022 | $113.29M | -34.4% |
| FY2021 | Dec 31, 2021 | $172.60M | -15.0% |
| FY2020 | Dec 31, 2020 | $203.16M | +16511.4% |
| FY2019 | Dec 31, 2019 | $1.22M | -94.8% |
| FY2018 | Dec 31, 2018 | $23.52M | -46.5% |
| FY2017 | Dec 31, 2017 | $43.98M | +1.1% |
| FY2016 | Dec 31, 2016 | $43.52M | -35.6% |
| FY2015 | Dec 31, 2015 | $67.54M | -20.4% |
| FY2014 | Dec 31, 2014 | $84.80M | +1398.5% |
| FY2013 | Dec 31, 2013 | $5.66M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $176.09M | +12.2% |
| Q1 FY2026 | Mar 31, 2026 | $191.92M | +13.9% |
| Q4 FY2025 | Dec 31, 2025 | $209.47M | +15.4% |
| Q3 FY2025 | Sep 30, 2025 | $144.64M | +53.7% |
| Q2 FY2025 | Jun 30, 2025 | $156.93M | +54.4% |
| Q1 FY2025 | Mar 31, 2025 | $168.56M | +147.4% |
| Q4 FY2024 | Dec 31, 2024 | $181.45M | +129.8% |
| Q3 FY2024 | Sep 30, 2024 | $94.09M | +6.4% |
| Q2 FY2024 | Jun 30, 2024 | $101.65M | +6.8% |
| Q1 FY2024 | Mar 31, 2024 | $68.13M | -36.0% |
| Q4 FY2023 | Dec 31, 2023 | $78.95M | -30.3% |
| Q3 FY2023 | Sep 30, 2023 | $88.47M | -40.5% |
| Q2 FY2023 | Jun 30, 2023 | $95.14M | -38.6% |
| Q1 FY2023 | Mar 31, 2023 | $106.41M | -34.0% |
| Q4 FY2022 | Dec 31, 2022 | $113.29M | -34.4% |
| Q3 FY2022 | Sep 30, 2022 | $148.59M | -17.8% |
| Q2 FY2022 | Jun 30, 2022 | $154.88M | -18.0% |
| Q1 FY2022 | Mar 31, 2022 | $161.26M | -16.2% |
| Q4 FY2021 | Dec 31, 2021 | $172.60M | -15.0% |
| Q3 FY2021 | Sep 30, 2021 | $180.70M | -9.2% |
| Q2 FY2021 | Jun 30, 2021 | $188.89M | +198.6% |
| Q1 FY2021 | Mar 31, 2021 | $192.41M | +174.5% |
| Q4 FY2020 | Dec 31, 2020 | $203.16M | +16511.4% |
| Q3 FY2020 | Sep 30, 2020 | $198.91M | +1961.6% |
| Q2 FY2020 | Jun 30, 2020 | $63.26M | +445.3% |
| Q1 FY2020 | Mar 31, 2020 | $70.10M | +288.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.22M | -94.8% |
| Q3 FY2019 | Sep 30, 2019 | $9.65M | -64.8% |
| Q2 FY2019 | Jun 30, 2019 | $11.60M | -58.4% |
| Q1 FY2019 | Mar 31, 2019 | $18.06M | -53.1% |
| Q4 FY2018 | Dec 31, 2018 | $23.52M | -46.5% |
| Q3 FY2018 | Sep 30, 2018 | $27.41M | -43.6% |
| Q2 FY2018 | Jun 30, 2018 | $27.85M | -17.2% |
| Q1 FY2018 | Mar 31, 2018 | $38.51M | +6.9% |
| Q4 FY2017 | Dec 31, 2017 | $43.98M | +1.1% |
| Q3 FY2017 | Sep 30, 2017 | $48.56M | -1.7% |
| Q2 FY2017 | Jun 30, 2017 | $33.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $36.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $43.52M | – |
| Q3 FY2016 | Sep 30, 2016 | $49.40M | – |
See a number that looks wrong?